Sign up for the new Critical Metals Report newsletter!

(6/7/11)

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials
Source: Streetwise Reports (01/20/2020)

InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials.

Platinum Group Metals' Shares Trade Up 35% on Waterberg Mine Prospects and Soaring PGM Demand
Source: Streetwise Reports (01/17/2020)

Shares of Platinum Group Metals Ltd. climbed to a new 52-week high price fueled by high demand and increases in platinum group metals prices. The firm claims its primary objective is now the advancement of the palladium dominant Waterberg Project in South Africa.

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation
Source: Streetwise Reports (01/16/2020)

Shares of NantKwest Inc. spiked as much as 85% higher, setting a new 52-week high price, after the company reported a series of positive results at the 38th JP Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were noted in as many as six different multiple tumor types when "natural killer" cells and T cells are activated simultaneously.

Pope Resources Shares Rise 35% on Rayonier $554 Million Takeover Bid
Source: Streetwise Reports (01/15/2020)

Pope Resources LP shares set a new 52-week intraday high price after the timber resources firm announced that it agreed to be acquired by Rayonier for $554 million, or $126.91 per unit. The transaction is expected to close in mid-year 2020 subject to approval of Pope's unitholders and customary regulatory approvals.

Transenterix Shares Trade Up 25% on FDA Filing for First Machine Vision System in Robotic Surgery
Source: Streetwise Reports (01/14/2020)

Shares of Transenterix opened 50% higher after the company reported that it has submitted a 510(k) submission to the FDA for the first machine vision system for use in robotic surgery.

The disruptive technology is 'poised to deliver significant advancement in bladder cancer detection.'

Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in four different solid tumor indications.

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study
Source: Streetwise Reports (01/10/2020)

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency.

Applied Genetic Tech's Shares Double on 6-Month X-Linked RP Study Results
Source: Streetwise Reports (01/09/2020)

Shares of Applied Genetic Technologies skyrocketed to a new 52-week high price after the company reported positive six-month data from its ongoing Phase 1/2 clinical study for treatment in X-Linked Retinitis Pigmentosa. The firm stated that the trial data suggests durable and meaningful improvements in central visual sensitivity and advised that it plans to initiate a pivotal trial by year-end 2020.

Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study
Source: Streetwise Reports (01/08/2020)

Applied Therapeutics' shares traded 25% higher after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20.